IN2015MN00464A - - Google Patents

Info

Publication number
IN2015MN00464A
IN2015MN00464A IN464MUN2015A IN2015MN00464A IN 2015MN00464 A IN2015MN00464 A IN 2015MN00464A IN 464MUN2015 A IN464MUN2015 A IN 464MUN2015A IN 2015MN00464 A IN2015MN00464 A IN 2015MN00464A
Authority
IN
India
Prior art keywords
present
chloro
salt
crystal
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Shoko Yoshida
Yuuichi Sugimoto
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2015MN00464A publication Critical patent/IN2015MN00464A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN464MUN2015 2012-09-06 2013-09-05 IN2015MN00464A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012195761 2012-09-06
PCT/JP2013/073865 WO2014038606A1 (ja) 2012-09-06 2013-09-05 ジスピロピロリジン誘導体の結晶

Publications (1)

Publication Number Publication Date
IN2015MN00464A true IN2015MN00464A (ko) 2015-09-04

Family

ID=50237214

Family Applications (1)

Application Number Title Priority Date Filing Date
IN464MUN2015 IN2015MN00464A (ko) 2012-09-06 2013-09-05

Country Status (13)

Country Link
US (8) US9359368B2 (ko)
EP (1) EP2894156B1 (ko)
JP (1) JP6016284B2 (ko)
KR (1) KR102217410B1 (ko)
CN (1) CN104812757B (ko)
BR (1) BR112015004816B1 (ko)
CA (1) CA2884238C (ko)
ES (1) ES2637150T3 (ko)
HK (1) HK1210172A1 (ko)
IN (1) IN2015MN00464A (ko)
RU (1) RU2647840C2 (ko)
TW (1) TWI586668B (ko)
WO (1) WO2014038606A1 (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN107428734A (zh) 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
EP3284466A4 (en) * 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3364966A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
KR20180064540A (ko) 2015-10-23 2018-06-14 다이이찌 산쿄 가부시키가이샤 암 치료를 위한 mdm2 억제제의 투여 요법
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
CA3209295A1 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
HRP20231537T1 (hr) 2016-12-01 2024-03-15 Arvinas Operations, Inc. Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
JP2021521112A (ja) 2018-04-04 2021-08-26 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. タンパク質分解の調節因子および関連する使用方法
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
BR0215156A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-imidazolinas como inibidores de mdm 2
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
AU2005243465B2 (en) 2004-05-18 2011-08-25 F. Hoffmann-La Roche Ag Novel CIS-imidazolines
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
CN101160314B (zh) * 2005-02-22 2012-05-23 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
TW200801011A (en) * 2006-02-07 2008-01-01 Astrazeneca Ab New compounds II
JP2009530236A (ja) 2006-03-13 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー スピロインドリノン誘導体
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CN101528223B (zh) 2006-08-30 2013-05-01 密执安州立大学董事会 Mdm2的新型小分子抑制剂和其用途
CA2662838A1 (en) 2006-09-21 2008-03-27 F. Hoffmann-La Roche Ag Oxindole derivatives
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CA2682483A1 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
PT2340021E (pt) 2008-09-18 2013-01-25 Hoffmann La Roche Pirrolidino-2-carboxamidas substituídas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
AU2010205201A1 (en) 2009-01-16 2011-08-04 Daiichi Sankyo Company,Limited Imidazothiazole derivative having proline ring structure
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 mdm2 길항제
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CA2800519A1 (en) 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
CN103210047B (zh) 2010-09-08 2018-07-17 巴斯夫欧洲公司 含n取代的二氮烯*二氧化物和/或n’-羟基-二氮烯*氧化物盐的含水抛光组合物
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
US8629133B2 (en) 2011-03-10 2014-01-14 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶

Also Published As

Publication number Publication date
CN104812757A (zh) 2015-07-29
US9359368B2 (en) 2016-06-07
EP2894156A4 (en) 2016-03-23
EP2894156A1 (en) 2015-07-15
US20180155355A1 (en) 2018-06-07
JPWO2014038606A1 (ja) 2016-08-12
BR112015004816A2 (pt) 2017-07-04
US9718830B2 (en) 2017-08-01
KR102217410B1 (ko) 2021-02-18
US20150210707A1 (en) 2015-07-30
US20170081334A1 (en) 2017-03-23
WO2014038606A1 (ja) 2014-03-13
CA2884238A1 (en) 2014-03-13
US10023578B2 (en) 2018-07-17
US20180155356A1 (en) 2018-06-07
TWI586668B (zh) 2017-06-11
TW201410681A (zh) 2014-03-16
HK1210172A1 (en) 2016-04-15
US20170081337A1 (en) 2017-03-23
JP6016284B2 (ja) 2016-10-26
US9884871B2 (en) 2018-02-06
US9718831B2 (en) 2017-08-01
US20160244458A1 (en) 2016-08-25
RU2647840C2 (ru) 2018-03-21
US20170081336A1 (en) 2017-03-23
CA2884238C (en) 2017-10-03
KR20150048140A (ko) 2015-05-06
BR112015004816B1 (pt) 2022-04-26
US9540386B2 (en) 2017-01-10
ES2637150T3 (es) 2017-10-11
CN104812757B (zh) 2016-11-09
EP2894156B1 (en) 2017-05-17
US10030030B2 (en) 2018-07-24
US9745315B2 (en) 2017-08-29
US20170081335A1 (en) 2017-03-23
RU2015112098A (ru) 2016-10-27

Similar Documents

Publication Publication Date Title
IN2015MN00464A (ko)
PH12020500162A1 (en) Process for the preparation of a pde4 inhibitor
GEP20156285B (en) Compounds and compositions as trk inhibitors
AU2018260844A1 (en) Processes of making and crystalline forms of a MDM2 inhibitor
WO2014028597A3 (en) 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12014502570A1 (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
IN2014MN02459A (ko)
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
GEP20166438B (en) Imidazopyrrolidinone compounds
NZ712207A (en) Tetrahydropyrrolothiazine compounds
NZ603789A (en) Heteroaryl compounds and methods of use thereof
IN2014MN00258A (ko)
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
EA201171008A1 (ru) Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
IN2015DN01815A (ko)
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MX361723B (es) Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2015DN03869A (ko)